Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
AOD-9604 is 16 amino acids long, whereas PT-141 is shorter as it has a length of 7 amino acids. AOD-9604 is made up of a sequence of Tyrosine, Leucine, Arginine, Isoleucine, Valine, Glutamine, Cysteine, Arginine, Serine, Valine, Glutamic acid, Glycine, Serine, Cysteine, Glycine, Phenylalanine. PT-141 is made up of a sequence of sequence data not available in the current dataset.
AOD-9604
GH1
PT-141
POMC
No related articles are linked to these peptides yet.